Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Review Article: THE 22 PLEIOTROPIC PROPERTIES OF STATIN AND CARDIOVASCULAR DISEASES The Roles of Atorvastatin with Its PPECCAT-GOMMESAAB Effects

Folia Medica Indonesiana · Vol. 45 No. 4 (2009)

ISSN
2355-8393, 2599-056X
Terbit
2009-10-01
Penerbit
Airlangga University
Bahasa
en

Abstrak

There are 22 possible pleiotropic atheroprotective effects of statin. Specifically, it was hypothesized that in addition to their beneficial lipid modulating activity, specific metabolites (but not the parent drug) of atorvastatin called AT.M (ATorvastatin Metabolite). Atorvastatin is very effective in lowering LDL-C levels, and the clinical evidence-based data have been proved by the results of prominent studies, such as AVERT (Pitt et al. 1999), ASAP (Smilde et al. 2001), MIRACL (Schwartz et al. 2001,Waters et al. 2002), and GREACE (Athyros et al. 2002), CARDS (Colhoun et al. 2005), REVERSAL (Nissen 2005), PROVE IT-TIMI 22 (Sever et al. 2005), ASCOT-LLA (Sever et al. 2005), ARMYDA-3 (Patti et al. 2006), TNT-Subgroup Analysis (Khus et al. 2007), ASCOT-LLA Extension (Sever et al. 2008), and SANDS (Howard et al. 2008). The aim of this article is to describe shortly pleiotropic properties of statins (which in part = 16 components can be indicated as PPECCAT-GOMMESAAB) from basic to possible clinical application (focus on atorvastatin), to general practitioners, residents, internists, and other associated specialists.

Kata kunci

Jaringan kolaborasi para penulis

8 penulis · 16 tautan kepenulisan bersama · 7 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • University of Brawijaya
  • Rumah Sakit Umum Pusat Dr. Sardjito
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Agung Sindu PranotoUniversitas Airlangga1
Hermina NovidaUniversitas Airlangga1
Jongky Hendro PrayitnoAfiliasi tidak diketahui1
Adeodatus Yuda HandayaRumah Sakit Umum Pusat Dr. Sardjito1
Djanggan SargowoUniversity of Brawijaya1
Diana LyrawatiUniversity of Brawijaya1
Mohammad Aris WidodoUniversity of Brawijaya1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Review Article: THE 22 PLEIOTROPIC PROPERTIES OF STATIN AND CARDIOVASCULAR DISEASES The Roles of Atorvastatin with Its PPECCAT-GOMMESAAB Effects</dc:title><dc:creator>Askandar Tjokroprawiro</dc:creator><dc:subject>atorvastatin</dc:subject><dc:subject>statins</dc:subject><dc:subject>pleiotropy</dc:subject><dc:subject>cardiovascular disease</dc:subject><dc:subject>atheroprotection</dc:subject><dc:subject>LDL cholesterol lowering</dc:subject><dc:subject>cardiovascular risk reduction</dc:subject><dc:description xml:lang="en">There are 22 possible pleiotropic atheroprotective effects of statin. Specifically, it was hypothesized that in addition to their beneficial lipid modulating activity, specific metabolites (but not the parent drug) of atorvastatin called AT.M (ATorvastatin Metabolite). Atorvastatin is very effective in lowering LDL-C levels, and the clinical evidence-based data have been proved by the results of prominent studies, such as AVERT (Pitt et al. 1999), ASAP (Smilde et al. 2001), MIRACL (Schwartz et al. 2001,Waters et al. 2002), and GREACE (Athyros et al. 2002), CARDS (Colhoun et al. 2005), REVERSAL (Nissen 2005), PROVE IT-TIMI 22 (Sever et al. 2005), ASCOT-LLA (Sever et al. 2005), ARMYDA-3 (Patti et al. 2006), TNT-Subgroup Analysis (Khus et al. 2007), ASCOT-LLA Extension (Sever et al. 2008), and SANDS (Howard et al. 2008). The aim of this article is to describe shortly pleiotropic properties of statins (which in part = 16 components can be indicated as PPECCAT-GOMMESAAB) from basic to possible clinical application (focus on atorvastatin), to general practitioners, residents, internists, and other associated specialists.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2009-10-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>http://journal.unair.ac.id/filerPDF/13%2008047%20Askandar%200829.pdf</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 45 No 4 (2009)</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language></oai_dc:dc>